Biogen launches new biosimilar therapy Flixabi in UK

Biogen has introduced its new biosimilar therapy Flixabi in the UK for use in the treatment of a range of inflammatory conditions.

The drug is a biosimilar version of Remicade, Johnson and Johnson's established immunology treatment, and is indicated for use in the treatment of Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Flixabi was approved by the European Commission in May and has demonstrated in a 54-week, phase III clinical study that it offers comparable safety and equivalent efficacy to Remicade.

According to Biogen, the conditions Flixabi is indicated for affect more than 600,000 people in the UK and can cost the NHS up to 470 million pounds every year.

Darren Clarkson, regional director for biosimilars at Biogen UK, said: "With the launch of Flixabi, we further our commitment to increasing patient choice and expanding access while helping to reduce the burden on healthcare systems."

This is the second biosimilar Biogen has launched in the UK this year, following the earlier release of Benepali. It is also the third biosimilar version of Remicade to be made available.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.